Title: Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer
Authors: QU C.f.SONG E.LI Y.RIZVI S.m.a.RAJA C.ROSS RAPOSTOLIDIS CHRISTOSALLEN Barry J.
Editors: MORGENSTERN ALFRED
Citation: CLINICAL & EXPERIMENTAL METASTASIS vol. 22 p. 575-586
Publisher: SPRINGER
Publication Year: 2005
JRC N°: JRC33606
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC33606
Type: Articles in Journals
Abstract: Purpose: The urokinase plasminogen activator (uPA) and its receptor (uPAR) are expressed by pancreatic cancer cells and can be targeted by the plasminogen activator inhibitor type 2 (PAI2). We have labeled PAI2 with 213Bi to form the alpha conjugate (AC), and have studied its in vitro cytotoxicity and in vivo efficacy.
JRC Institute:Institute for Transuranium Elements

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.